Unity Biotechnology (NASDAQ:UBX) Stock Price Up 3.1% – Here’s Why

Posted by Caroline Horne on Feb 7th, 2025

Shares of Unity Biotechnology, Inc. (NASDAQ:UBX – Get Free Report) traded up 3.1% during mid-day trading on Wednesday . The stock traded as high as $2.34 and last traded at $2.30. 126,334 shares changed hands during trading, a decline of 72% from the average session volume of 443,488 shares. The stock had previously closed at $2.23.

Analyst Upgrades and Downgrades

Separately, Chardan Capital started coverage on Unity Biotechnology in a research report on Friday, January 10th. They set a “buy” rating and a $6.00 target price on the stock.

Check Out Our Latest Analysis on UBX

Unity Biotechnology Stock Performance

The stock’s fifty day moving average price is $1.52 and its 200-day moving average price is $1.45. The firm has a market cap of $36.06 million, a PE ratio of -1.63 and a beta of 0.91.

Unity Biotechnology (NASDAQ:UBX – Get Free Report) last posted its quarterly earnings results on Monday, November 4th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.02. Sell-side analysts forecast that Unity Biotechnology, Inc. will post -1.45 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Unity Biotechnology

A hedge fund recently raised its stake in Unity Biotechnology stock. Geode Capital Management LLC grew its stake in Unity Biotechnology, Inc. (NASDAQ:UBX – Free Report) by 9.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 163,242 shares of the company’s stock after acquiring an additional 14,199 shares during the quarter. Geode Capital Management LLC owned about 0.97% of Unity Biotechnology worth $240,000 at the end of the most recent quarter. Institutional investors and hedge funds own 29.49% of the company’s stock.

Unity Biotechnology Company Profile

(Get Free Report)

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.